doi:10.1007/s12250-008-2995-y

Aaron L, Lidove O, Yousry C. Human herpesvirus 8-positive Castleman disease in human im-munodeﬁciency virus-infected patients: the impact of highly active antiretroviral therapy[J]. Clin Infect Dis, 2002, 35(): 880-882. doi: 10.1086/cid.2002.35.issue-7
Abele G, Cox S, Bergman L. Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (-) enantiomers of (R, S)-9-[4-hydroxy-2-(hydroxy-methyl) butyl] guanine, in comparison to other closely related acyclic nucleosides[J]. Antiviral Chem Chemother, 1991, 2(): 163-169. doi: 10.1177/095632029100200306
Alagiozoglou L, Morris L, Bredell H. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa[J]. Epidemiol Infect, 2003, 131(): 1125-1129. doi: 10.1017/S0950268803001146
Bahl S, Theis B, Nishri D, et al. 2008. Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control, http://www.springerlink.com/content/y1423n681-4037804/fulltext.pdf
Bani-Sadr F, Fournier S, Molina J M. Relapse ofKaposi's sarcoma inHIV-infected patients switching fromaprotease inhibitor toanon-nucleoside reverse trans-criptase inhibitor-based highly active antiretroviral therapy regimen[J]. AIDS, 2003, 17(): 1580-1581. doi: 10.1097/00002030-200307040-00028
Barillari G, Buonaguro L, Fiorelli V. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: implications for AIDS-Kaposi's sarcoma pathogenesis[J]. J Immunol, 1992, 149(): 3727-3734.
Beral V. Epidemiology of Kaposi's sarcoma[J]. Cancer Surv, 1991, 10(): 5-22.
Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Cast-leman disease[J]. Blood, 2004, 103(): 4368-4369. doi: 10.1182/blood-2004-01-0158
Biggar R J, Whitby D, Marshall V. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype[J]. J Infect Dis, 2000, 181(): 1562-1568. doi: 10.1086/jid.2000.181.issue-5
Bottieau E, Colebunders R, Schroyens W. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy[J]. Acta Clin Belg, 2000, 55(): 97-101. doi: 10.1080/17843286.2000.11754278
Bower M, Fox P, Fife K. Highly active anti-retroviral therapy (HAART) prolongs time to treat-ment failure in Kaposi's sarcoma[J]. AIDS, 1999, 13(): 2105-2111. doi: 10.1097/00002030-199910220-00014
Casper C, Nichols W G, Huang M L. Remis-sion of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment[J]. Blood, 2004, 103(): 1632-1634. doi: 10.1182/blood-2003-05-1721
Cattelan A, Calabro M, Gasperini P. Acquired immunodeﬁciency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome[J]. J Natl Cancer Inst Monogr, 2001, 28(): 44-49.
Chang Y, Cesarman E, Pessin M S. Identiﬁ-cation of herpesvirus-like sequences in AIDS-associated Kaposi's sarcoma[J]. Science, 1994, 266(): 1865-1869. doi: 10.1126/science.7997879
Clifford G M, Polesel J, Rickenbach M. Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeﬁciency, smoking, and highly active antiretroviral therapy[J]. J Natl Cancer Inst, 2005, 97(): 425-432. doi: 10.1093/jnci/dji072
Crum-Cianﬂone N F, Wallace M R, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy[J]. AIDS, 2006, 20(): 1567-1569. doi: 10.1097/01.aids.0000237381.92303.61
Dilnur P, Katano H, Wang Z H. Classic type of Kaposi's sarcoma and human herpesvirus 8 infection in Xinjiang, China[J]. Pathol Int, 2001, 51(): 845-852. doi: 10.1046/j.1440-1827.2001.01293.x
Diz Dios P, Ocampo Hermida A, Miralles Alvarez C. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy[J]. Oral Oncol, 1998, 34(): 236-238. doi: 10.1016/S1368-8375(97)00082-1
Dukers N H, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know[J]. AIDS, 2003, 17(): 1717-1730. doi: 10.1097/00002030-200308150-00001
Eltom M A, Jemal A, Mbulaiteye S M. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998[J]. J Natl Cancer Inst, 2002, 94(): 1204-1210. doi: 10.1093/jnci/94.16.1204
Ensoli B, Barillari G, Salahuddin S Z. Tat protein of HIV-1 stimulates growth of AIDS-Kaposi's sarcoma-derived cells[J]. Nature, 1990, 345(): 84-86. doi: 10.1038/345084a0
Franceschi S, Maso L D, Rickenbach M. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy[J]. Br J Cancer, 2008, 99(): 800-804. doi: 10.1038/sj.bjc.6604520
Glesby M J, Hoover D R, Weng S. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study[J]. J Infect Dis, 1996, 173(): 1477-1480. doi: 10.1093/infdis/173.6.1477
Grandadam M, Dupin N, Calvez V. Exacerbations of clinical symptoms in human immunodeﬁ-ciency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells[J]. J Infect Dis, 1997, 175(): 1198-1201. doi: 10.1086/jid.1997.175.issue-5
Grundhoff A, Ganem D. Inefﬁcient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis[J]. J Clin Invest, 2004, 113(): 124-136. doi: 10.1172/JCI200417803
Gustafson E A, Schinazi R F, Fingeroth J D. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate speciﬁcity that efﬁciently phosphorylates zidovudine but not ganciclovir[J]. J Virol, 2000, 74(): 684-692. doi: 10.1128/JVI.74.2.684-692.2000
He F, Wang X, He B. Human herpesvirus 8: serovprevalence and correlates in tumor patients from Xinjiang, China[J]. J Med Virol, 2007, 79(): 161-166. doi: 10.1002/(ISSN)1096-9071
Hocqueloux L, Agbalika F, Oksenhendler E. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy[J]. AIDS, 2001, 15(): 280-282. doi: 10.1097/00002030-200101260-00023
Huang L M, Chao M F, Chen M Y. Reciprocal regulatory interaction between human herpes-virus 8 and human immunodeﬁciency virus type 1[J]. J Biol Chem, 2001, 276(): 13427-13432. doi: 10.1074/jbc.M011314200
Ioannidis J P, Collier A C, Cooper D A. Clinical efﬁcacy of high-dose acyclovir in patients with human immunodeﬁciency virus infection: a meta-analysis of randomized individual patient data[J]. J Infect Dis, 1998, 178(): 349-359. doi: 10.1086/515621
Iwayama S, Ono N, Ohmura Y. Antiherpes-virus activities of (1kS, 2kR)-9-[[1k, 2k-bis (hydroxymethyl) -cycloprop-1k-yl]methyl] (A-5021) in cell culture[J]. Antimi -crob Agents Chemother, 1998, 42(): 1666-1670.
Jung C, Bogner J R, Goebel F. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy[J]. Eur J Med Res, 1998, 3(): 439-442.
Katano H, Sato Y, Kurata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease[J]. Virology, 2000, 269(): 335-344. doi: 10.1006/viro.2000.0196
Katano H, Sato Y, Itoh H, Sata T. Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases[J]. J Hum Virol, 2001, 4(): 96-102.
Katz M H, Hessol N A, Buchbinder S P. Temporal trends of opportunistic infections and mali-gnancies in homosexual men with AIDS[J]. J Infect Dis, 1994, 170(): 198-202. doi: 10.1093/infdis/170.1.198
Kedes D H, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy[J]. J Clin Invest, 1997, 99(): 2082-2086. doi: 10.1172/JCI119380
Keller S A, Schattner E J, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells[J]. Blood, 2000, 96(): 2537-2542.
Krischer J, Rutschmann O, Hirschel B. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study[J]. J Am Acad Dermatol, 1998, 38(): 594-598. doi: 10.1016/S0190-9622(98)70124-0
Laney A S, Dollard S C, Jaffe H W. Repeatedmeasures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV[J]. AIDS, 2004, 18(): 1819-1826. doi: 10.1097/00002030-200409030-00011
Leao J C, Kumar N, McLean K A. Effect of human immunodeﬁciency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeﬁciency virus-1-infected patients[J]. J Med Virol, 2000, 62(): 416-420. doi: 10.1002/(ISSN)1096-9071
Lebbe C, Blum L, Pellet C. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma[J]. AIDS, 1998, 12(): F45-49. doi: 10.1097/00002030-199807000-00002
Little R F, Merced-Galindez F, Staskus K. A pilot study of cidofovir in patients with Kaposi sarcoma[J]. J Infect Dis, 2003, 187(): 149-153. doi: 10.1086/jid.2003.187.issue-1
Lock M J, Thorley N, Teo J. Azidodeoxythy-midine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase[J]. J Antimicrob Chemother, 2002, 49(): 359-366. doi: 10.1093/jac/49.2.359
Luppi M, Trovato R, Barozzi P. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir[J]. Leukemia, 2005, 19(): 473-476. doi: 10.1038/sj.leu.2403646
Martin D F, Kuppermann B D, Wolitz R A. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant[J]. N Engl J Med, 1999, 340(): 1063-1070. doi: 10.1056/NEJM199904083401402
Martinelli C, Zazzi M, Ambu S. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir[J]. AIDS, 1998, 12(): 1717-1719.
Medveczky M M, Horvath E, Lund T. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus[J]. AIDS, 1997, 11(): 1327-1332. doi: 10.1097/00002030-199711000-00006
Miller G, Heston L, Grogan E. Selective switch between latency and lytic replication of KSV and EBV in dually infected body-cavity lymphoma cells[J]. J Virol, 1997, 71(): 314-324.
Mocroft A, Youle M, Gazzard B. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group[J]. AIDS, 1996, 10(): 1101-1105.
Monini P, Colombini S, Sturzl M. Reacti-vation and persistence of HHV-8 infection in B-cells and monocytes by Th1 cytokines increased in Kaposi's sarcoma[J]. Blood, 1999, 93(): 4044-4058.
Murphy M, Armstrong D, Sepkowitz K A. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor[J]. AIDS, 1997, 11(): 261-262.
Neyts J, Andrei G, Snoeck R. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1, 3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication[J]. Antimicrob Agents Chemother, 1994, 38(): 2710-2716. doi: 10.1128/AAC.38.12.2710
Neyts J, J hne G, Andrei G. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1, 3-dihydroxy-2-propoxy) methyl] purine[J]. Antimicrob Agents Chemother, 1995, 39(): 56-60. doi: 10.1128/AAC.39.1.56
Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8[J]. Antimicrob Agents Chemother, 1997, 41(): 2754-2756.
Norbeck D W, Kern E, Hayashi S. Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS[J]. J Med Chem, 1990, 33(): 1281-1285. doi: 10.1021/jm00167a002
Oksenhendler E, Carcelain G, Aoki Y. High levels of human herpesvirus 8 viral load, human inter-leukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients[J]. Blood, 2000, 96(): 2069-2073.
Pastore R D, Chadburn A, Kripas C. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma[J]. Br J Haematol, 2000, 111(): 1112-1115. doi: 10.1046/j.1365-2141.2000.02478.x
Pati S, Pelser C B, Dufraine J. Antitumori-genic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma[J]. Blood, 2002, 99(): 3771-3779. doi: 10.1182/blood.V99.10.3771
Pellet C, Chevret S, Blum L. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy[J]. J Invest Dermatol, 2001, 117(): 858-863. doi: 10.1046/j.0022-202x.2001.01465.x
Portsmouth S, Stebbing J, Gill J. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma[J]. AIDS, 2003, 17(): F17-22. doi: 10.1097/00002030-200307250-00001
Rey D, Schmitt M P, Partisani M. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks[J]. J Acquir Immune Deﬁc Syndr, 2001, 27(): 459-462. doi: 10.1097/00042560-200108150-00006
Schaeffer H J, Beauchamp L, de Miranda P. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group[J]. Nature, 1978, 272(): 583-585. doi: 10.1038/272583a0
Schulz T F. Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8[J]. Adv Cancer Res, 1999, 76(): 121-160. doi: 10.1016/S0065-230X(08)60775-7
Sgadari C, Barillari G, Toschi E. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma[J]. Nat Med, 2002, 8(): 225-232. doi: 10.1038/nm0302-225
Sgadari C, Monini P, Barillari G. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth[J]. Lancet Oncol, 2003, 4(): 537-547. doi: 10.1016/S1470-2045(03)01192-6
Shimba N, Nomura A M, Marnett A B. Herpesvirus protease inhibition by dimer disruption[J]. J Virol, 2004, 78(): 6657-6665. doi: 10.1128/JVI.78.12.6657-6665.2004
Smith M S, Bloomer C, Horvat R. Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeﬁciency virus-positive patients and correlation with serologic measure-ments[J]. J Infect Dis, 1997, 176(): 84-93. doi: 10.1086/jid.1997.176.issue-1
Tavio M, Nasti G, Spina M. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma[J]. Ann Oncol, 1998, 9(): 923-923. doi: 10.1023/A:1008359628245
Valencia M E, Moreno V, Martinez P. Favorable outcome of Castleman's disease treated with oral valganciclovir[J]. Med Clin (Barc), 2005, 125(): 399-. doi: 10.1157/13079178
Wang J, Froeyen M, Hendrix C. The cyclo-hexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclo-hexenyl-guanine[J]. J Med Chem, 2000, 43(): 736-745. doi: 10.1021/jm991171l
Wilkinson J, Cope A, Gill J. Identiﬁcation of Kaposi's sarcoma-associated herpesvirus (KSHV)-speciﬁc cytotoxic T-lymphocyte epitopes and evaluation of reconsti-tution of KSHV-speciﬁc responses in human immunodeﬁ-ciency virus type 1-infectedpatients receivinghighly active antiretroviral therapy[J]. J Virol, 2002, 76(): 2634-2640. doi: 10.1128/JVI.76.6.2634-2640.2002
Ziegler J, Newton R, Bourboulia D. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda[J]. Int J Cancer, 2003, 103(): 233-240. doi: 10.1002/(ISSN)1097-0215
Zietz C, Bogner J R, Goebel F D. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS[J]. N Engl J Med, 1999, 340(): 1923-1924.